Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Clinical trial NCT05389423 · RECRUITING

Trial details

NCT number: NCT05389423
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Diffuse Large Cell Lymphoma Non-Hodgkin Lymphoma Burkitt Lymphoma Plasmablastic Lymphoma B-Cell Neoplasm

Start date: 2023-06-27
Primary completion: 2028-06-01
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.